Neurology

New 5-year data from phase 3 studies show that patients treated earlier with ocrelizumab (Ocrevus) had better outcomes on multiple measures of multiple sclerosis disease activity.

Siponimod is an oral, once-daily medication for the treatment of multiple sclerosis in adults.

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children.

Brain inflammation caused by critical illness and infection may lead to the observed reduction in brain volume.

Lymphatic vessels surrounding the brain may play a key role in the development and progression of multiple sclerosis.

The FDA did not identify any new or unexpected safety findings with pimavanserin (Nuplazid), nor findings that are inconsistent with the established safety profile currently described in the drug label.

The phase 3 PARADIGMS clinical trial is the first-ever study designed for children and adolescents aged 10 to 17 years old with relapsing forms of multiple sclerosis.

Patients with multiple sclerosis incur higher costs and experience lower health-related quality of life as their disability increases

Growth in midlife mortality includes conditions such as heart disease, liver cancer, pulmonary disease, obesity, and neurologic disorders.

Top news of the week from Specialty Pharmacy Times.

B cells activate T cells in the blood to cause inflammation and brain lesions in patients with multiple sclerosis.

Study shows a novel treatment approach that could prevent gene changes associated with the disease.

Top news of the day from across the health care landscape.

Treatment with ibudilast reduced the progression of brain atrophy in patients with progressive multiple sclerosis compared with a placebo.

Ozanimod reduced the number of brain lesions and lowered relapse rates in patients with relapsing multiple sclerosis.

The FDA has approved riluzole (Tigultik, ITF Pharma) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS).

The approval of riluzole oral suspension fills a therapeutic need for patients with amyotrophic lateral sclerosis who develop swallowing impairment.

Patients with multiple sclerosis who smoked cigarettes had higher rates of respiratory complications and increased sedentary lifestyle.

Supplementing a commonly used treatment approach with an additional inhibitor could help overcome resistance in glioblastoma.

Final approval for Sympazan, the oral soluble film formulation of clobazam, is pending the expiration of the orphan drug exclusivity period for ONFI.

Cannabidiol treatment increased the production of inflammatory suppressor cells in mice, which reduced the clinical signs of MS.

A synthetic chemical caused the self-destruction of glioblastoma tumor cells transferred from human patients into mice.

Amyotrophic lateral sclerosis and frontotemporal dementia exhibit key similarities in underlying molecular mechanisms tied to the dysfunction of RNA-binding proteins.

Molecular link found between aging and a major genetic cause of 2 neurodegenerative disorders.

Researchers uncover myelocortical multiple sclerosis, a new subtype of the disease that features neurodegeneration but lacks white matter myelin loss in the brain.

Machine-learning technique reduces toxic treatment dosing for glioblastoma while maintaining tumor-shrinking benefits.

The use of benzodiazepines and related z-drugs was found to be associated with a modest increase in the risk of Alzheimer disease in a case-control trial.

Study evaluates the effect of multiple sclerosis treatment alemtuzumab (Lemtrada) on the B-cell component of MS.

Assessment of neurofilament light chain levels offers real-time, efficient measure marker of multiple sclerosis progression.

Certain magnetic resonance imaging (MRI) parameters correlated with a greater risk of recurrence and progression to multiple sclerosis within the first year following diagnosis of clinically isolated syndrome.